Mark L. Baum
2018
In 2018, Mark L. Baum earned a total compensation of $1.1M as Chief Executive Officer at Imprimis Pharmaceuticals, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $424,954 |
|---|---|
| Option Awards | $204,000 |
| Salary | $410,706 |
| Stock Awards | $4,350 |
| Other | $13,116 |
| Total | $1,057,126 |
Baum received $425K in non-equity incentive plan, accounting for 40% of the total pay in 2018.
Baum also received $204K in option awards, $410.7K in salary, $4.4K in stock awards and $13.1K in other compensation.
Rankings
In 2018, Mark L. Baum's compensation ranked 8,953rd out of 14,244 executives tracked by ExecPay. In other words, Baum earned more than 37.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,953 out of 14,244 | 37th |
Division Manufacturing | 3,564 out of 5,762 | 38th |
Major group Chemicals And Allied Products | 1,346 out of 2,125 | 37th |
Industry group Drugs | 1,129 out of 1,814 | 38th |
Industry Pharmaceutical Preparations | 879 out of 1,388 | 37th |
Source: SEC filing on April 25, 2019.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2018.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019